Bausch Health Companies Inc. (NYSE:BHC) saw its stock price surge 5.99% in after-hours trading on Wednesday after reporting impressive fourth quarter and full-year 2024 results. The company's strong performance was driven by robust growth across its key business segments, driven by rising demand for its flagship products and strategic investments.

For the fourth quarter, Bausch Health posted revenues of $2.56 billion, exceeding analysts' expectations of $2.52 billion. This represents a 6% year-over-year increase, fueled by growth in the company's Salix, Solta Medical, and Bausch + Lomb segments. The Salix segment, which focuses on gastrointestinal products, witnessed a 9% revenue jump, while Solta Medical, the company's medical aesthetics business, saw a remarkable 34% growth.

Perhaps most notably, Bausch Health's eye health subsidiary, Bausch + Lomb, reported a 9% increase in revenues to $1.28 billion, driven by double-digit growth in its contact lens category and strength across its surgical portfolio. The company's vision care and pharmaceutical divisions were the primary growth drivers for Bausch + Lomb during the quarter.

Looking ahead, Bausch Health provided an encouraging outlook for 2025, forecasting revenues between $9.9 billion and $10.15 billion, with Bausch + Lomb expected to contribute between $4.95 billion and $5.05 billion. The company's adjusted EBITDA guidance for 2025 ranges from $3.525 billion to $3.675 billion, reflecting its commitment to sustainable and profitable growth.

Investors have reacted positively to Bausch Health's strong financial performance and promising growth prospects, as evidenced by the stock's after-hours surge. The company's diverse portfolio, strategic investments, and focus on innovation position it well to capitalize on emerging opportunities across its core markets.